WBR0642
Author | [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian)]] |
---|---|
Exam Type | ExamType::USMLE Step 1 |
Main Category | MainCategory::Microbiology, MainCategory::Pharmacology |
Sub Category | SubCategory::Infectious Disease |
Prompt | [[Prompt::A pharmaceutical company is manufacturing a novel antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin to counteract the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose?]] |
Answer A | AnswerA::RNA methylation inhibitors |
Answer A Explanation | AnswerAExp::Inhibition of RNA methylation can, in theory, help decrease resistance to macrolides since it targets the main resistance mechanism. |
Answer B | AnswerB::Drug acetylation inhibitors |
Answer B Explanation | AnswerBExp::Inhibition of acetylation targets the main mechanism of aminoglycoside resistance rather than that of macrolides. |
Answer C | AnswerC::Beta-lactamase inhibitors |
Answer C Explanation | AnswerCExp::Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. |
Answer D | AnswerD::Drug efflux pump blockers |
Answer D Explanation | AnswerDExp::Although drug efflux can be seen as a mechanism of resistance to macrolides, it is minor compared to rRNA methylation. |
Answer E | AnswerE::Drug adenylation inhibitors |
Answer E Explanation | AnswerEExp::Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. |
Right Answer | RightAnswer::A |
Explanation | [[Explanation::
|
Approved | Approved::Yes |
Keyword | WBRKeyword::Antibiotic resistance, WBRKeyword::Macrolides, WBRKeyword::Methylation |
Linked Question | Linked:: |
Order in Linked Questions | LinkedOrder:: |